Abstract
Introduction
Colorectal cancer (CRC) is the third most common cancer worldwide with poor prognosis and survival accounting for more than 600,000 deaths globally in 2008 [1] . Most CRCs undergo a well described multistage pathogenesis known as the adenomacarcinoma sequence involving the progression of benign adenomas to carcinoma over 10-17 years [2] . Investigations into the underlying molecular mechanisms and genetic events occurring at each stage of pathogenesis have revealed this process to be multifactorial, involving chromosomal abnormalities, loss of tumour suppressor genes and activation of oncogenes [3] .
Familial adenomatous polyposis (FAP) accounts for ~1% of all CRC cases and is the result of inherited mutations in the adenomatous polyposis coli (APC) tumour suppressor gene [4] . APC mutation leads to formation of many benign dysplastic polyps and adenomas in the small and large intestines and a 90% lifetime chance of progression to CRC [3] . APC loss is also detected in ~80% of sporadic CRCs making it one of the most common initiating genetic alterations in CRC [5] . The molecular mechanisms driving progression of APC-initiated adenomas to adenocarcinomas are poorly understood.
The phosphoinositide 3-kinase (PI3K)/AKT pathway plays a critical role in regulating numerous cellular processes critical in cancer development, including growth, proliferation, migration, apoptosis and survival [6] . Mutations in PIK3CA, the gene cancers including 20-30% of sporadic CRCs [7, 8] . Around 80% of these mutations cluster in three hot-spots; two in the helical domain (E542 and E545) and one in the kinase domain (H1047) [7, 8] . PIK3CA mutations have been detected in CRCs but not adenomas [8] suggesting their involvement in the later stages of CRC progression.
We have generated mice harbouring the most commonly detected PIK3CA mutation in human cancer (H1047R) conditionally knocked into the endogenous Pik3ca locus to explore the consequences of Pik3ca mutation in the gastrointestinal tract. In a system ideal for mimicking sporadic disease, we demonstrate that the Pik3ca H1047R mutation, by itself, is not tumourigenic. However when expressed in combination with the loss of Apc gene function, we observe invasive intestinal adenocarcinomas. This demonstrates -catenin pathways and the development of these adenocarcinomas.
Experimental

Mice
Mice harbouring a single latent, Cre recombinase (Cre)-inducible knock-in of the Pik3ca H1047R mutation (Pik3ca Lat-H1047R ) [9] and/or two Cre-inducible Apc loss-offunction alleles (Apc 580S/580S ) [10] were crossed with mice heterozygously expressing RU486-activatable Cre-progesterone receptor ligand-binding domain fusion knocked into the intestinal epithelial cell-specific Gpa33 locus (Gpa33Cre PR2 ) [11] . Mice generated (equal numbers of male and females) expressed heterozygous mutant Pik3ca H1047R and/or homozygous Apc loss of function (now Apc 580D/580D when alleles deleted) in the gastrointestinal tract. Transgenic B6;129S4-Gt(ROSA)26Sor tm1Sor /J (Rosa lacZ ) reporter mice were used for verification of Cre-mediated recombination [12] . All mice strains were maintained on C57BL/6 backgrounds. All animal experiments were approved by the Peter MacCallum Cancer Centre Animal Experimental Ethics Committee and conducted in accordance with the NHMRC Australian Code of Practice for the Care and Use of Animals for Scientific Purposes. Mice were closely monitored and humanely euthanized when they exhibited >10% weight loss, rectal bleeding or other signs of distress.
Induction of conditional Cre recombinase expression
To induce recombination, all mice were fed chow containing RU486 at a concentration of 20mg/kg (dissolved in ethanol, mixed with peanut oil, and added to mouse food softened with sucrose water) for four weeks from 6 weeks of age.
-Galactosidase staining
Intestinal tissues from Gpa33Cre PR2 :Rosa lacZ and Rosa lacZ control mice were harvested, rolled, fixed, embedded in optimal cutting temperature media for cryosectioning -galactosidase as previously described [13] .
Histology and immunohistochemistry
Small and large intestines of mice were removed and flushed with phosphate-buffered saline. A small piece of the proximal end of each, and any tumours if present, were snap frozen for RNA extraction. Remaining intestinal tissues were fixed as a "Swiss roll" on surgical tape in 10% neutral buffered formalin for 24 hours before paraffin embedding.
Sections were stained with haematoxylin/eosin (H&E) for histological analysis or -catenin (BD Biosciences, Franklin Lakes NJ, USA), p-Akt S473 (CS3787, Cell Signalling Technology, Danvers MA, USA), pAkt T308 (CS4056, Cell Signalling Technology) and pRps6 (CS2211, Cell Signalling Technology).
Sequencing
To confirm knock-in of the Pik3ca H1047R mutation, RNA was extracted from tissues and tumours and reverse transcribed to cDNA which was sequenced with Pik3ca-specific primers (forward, 5' -CAAGAGTACACCAAGACCAGAGAGTT -3' and reverse, 5' -TCCAATCCATTTTTGTCGTCC -3') using PCR cycle conditions of 95ºC for 30 seconds, 55ºC for 30 seconds and 72ºC for 45 seconds for 35 cycles.
Results
Confirmation of GpaA33Cre--galactosidase expression
The efficiency of Gpa33-driven Cre-mediated recombination, and thus conditional induction of Pik3ca H1047R expression in the gastrointestinal tract, was assessed using the Cre-inducible Rosa26 lacZ reporter mouse strain ( Figure 1A ). Cre-recombination was observed in 1-5% of crypts in the small and large intestines while no staining was detected in other tissues such as the liver ( Figure 1B ). As the mouse intestinal epithelium renews every 4-5 days, only recombination that occurs in the stem cell at the base of the crypt is reflected in positi -galactosidase staining beyond a few days.
Expression of the Pik3ca
H1047R mutation alone in the intestines does not initiate tumourigenesis To explore the role of Pik3ca H1047R mutation in intestinal cancer in vivo, we crossed Pik3ca
Lat-H1047R mice ( Figure 1C , [9] ) with Gpa33 CrePR2 mice [11] . The resulting Gpa33
CrePR2/+ :Pik3ca
Lat-H1047R/+ mice express wild-type Pik3ca until fed the progesterone agonist RU486 which induces Cre expression leading to the heterozygous expression of Pik3ca H1047R in the gastrointestinal tract. Following induction, mice expressing heterozygous Pik3ca H1047R were monitored for up to 2 years at which time they were sacrificed and the gastrointestinal tract analysed. No evidence of intestinal tumours or adenomas were detected (blue line in Figure 2C , Table 1 ).
H1047R mutation and Apc loss in the intestine synergize to cause tumourigenesis To explore if Pik3ca H1047R mutation could promote intestinal tumourigenesis in the context of homozygous Apc loss, we crossed the Gpa33Cre PR2/+ :Pik3ca
Lat-H1047R/WT with the conditional Apc 580S mouse in which exon 14 of the Apc gene is flanked by loxP sites [10] . RU486 exposure to both the control Gpa33Cre PR/+ :Apc 580S/580S mice and the double mutant Gpa33Cre PR2/+ :Pik3ca
Lat-H1047R/WT
:Apc 580S/580S mice induces Cre resulting in exon 14 deletion and a frameshift at codon 580 in both alleles of the Apc gene leading to the generation of a truncated, non-functional Apc protein ( Figure  1D) ) and Pik3ca H1047R (Gpa33Cre PR2/+ :Pik3ca H1047R/WT ) mice which did not present with any intestinal tumours (p<0.0001, Figure 2A ). The double mutant Pik3ca H1047R :Apc 580D/580D mice presented with up to 3 tumour masses greater than 4x4mm in size in both the small intestine ( Figure 2Bi ) and colon ( Figure 2Bii , Table 1 ).
Histological analysis identified tumours in Pik3ca
H1047R
:Apc 580D/580D mice as aggressive adenocarcinomas with extensive invasion into the submucosa ( Figure 2D ). Areas of dysplasia were also observed adjacent to the adenocarcinomas. Adenocarcinomas were distributed throughout the intestine (9 in the duodenum, 6 in the jejunum, 7 in the ileum and 5 in the distal colon, Figure 2C ). Three Pik3ca
:Apc 580D/580D mice (7%) presented with 1-4 small (<4mm) polyps observed macroscopically in addition to adenocarcinoma. These were pathologically confirmed as adenomas, although some exhibited early signs of invasion ( Figure 2D ). No single mutant mice developed adenocarcinomas and only one Apc 580D/580D mouse (4%) developed adenomas.
Sanger sequencing confirmed presence of the Pik3ca H1047R mutation, and the silent base changes engineered into the mutant Pik3ca exon 20, in the adenocarcinomas ( Figure 2E ). IHC staining for phosphorylated S6 (pRps6), a downstream target of PI3K/Akt activity, demonstrated consistent staining across tumours (Figure 3Ai ) which was more intense than in adjacent normal intestine (Figure 3Aii ) confirming increased PI3K pathway activity in the tumours.
The Pik3ca
H1047R mouse was also crossed with a second Apc mouse strain, the Apc Min mouse, which possesses a heterozygous germline Apc mutation predisposing mice to development of multiple adenomas [14] . As previously demonstrated, the latency for intestinal tumour-free survival in Pik3ca H1047R :Apc 580D/580D mice is ~200 days ( Figure  2B ). The Apc Min mouse strain have a reduced lifespan (<150 days) as a result of anaemia associated with polyp burden in the small intestine ( Figure 1A) . No difference in the proportion of adenomas observed across the small and large intestines was detected between Apc Min alone and Pik3ca H1047R :Apc Min mice ( Figure  4B ). Yet despite this narrow window in which tumourigenesis can occur, one of the twelve (8%) Pik3ca H1047R :Apc Min mice developed a large invasive adenocarcinoma with confirmed presence of Pik3ca H1047R mutation and Apc loss ( Figure C ). The single Pik3ca H1047R :Apc Min mouse which possessed an intestinal adenocarcinoma also developed a colonic adenoma which did not express the Pik3ca H1047R mutation ( Figure 1D) -catenin levels characteristic of Apc loss of function ( Figure 1E ).
Loss of Cdx2 expression observed in adenocarcinomas in areas of enhanced
-catenin expression -catenin localization was used to evaluate loss of Apc function. High levels of -catenin staining, corresponding to regions of Apc depletion, are clearly visible in tumours compared to predominately cytoplasmic staining observed in the surrounding normal tissue (Figures 3B-C) . Interestingly, in Pik3ca H1047R :Apc
tumour -catenin staining, we observed a complete loss of Cdx2 expression ( Figure 3B-C) .
Development of hepatocellular carcinomas in all mice as a result of hypomorphic unrecombined Apc alleles
All Apc 580D/580D mice, regardless of their Pik3ca status, developed hepatocellular carcinomas (HCCs) which required the mice to be sacrificed (Supplementary figure 1A-C) in spite of the fact that RU486 induction of Gpa33Cre PR2 does not express Cre in the liver ( Figure 1B) . The lack of expression of the Pik3ca H1047R mutation in the HCCs and normal liver in these mice was confirmed by sequencing RNA extracted from these tissues (Supplementary Figure 1D) . Previous research has demonstrated the presence of loxP cassettes in this strain to be hypomorphic and sufficient to reduce activity of the floxed Apc alleles prior to recombination (Apc 580S/580S
) [15] . The liver is particularly sensitive to this resulting in HCC development even with unrecombined alleles. Here, HCC growth resulted in mice being sacrificed before intestinal tumour development accounting for the incomplete (59%) penetrance of tumour formation in Pik3ca A c c e p t e d M a n u s c r i p t
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Discussion
Even though mutations in the PIK3CA gene are commonly found in human CRC, the underlying molecular role they play in the mechanisms of intestinal carcinogenesis have not been fully elucidated. Here, we describe a model in which the physiological expression of the Pik3ca H1047R mutation synergizes with the targeted loss of Apc to induce intestinal tumourigenesis. We demonstrate that Pik3ca H1047R expression alone is insufficient to initiate intestinal tumourigenesis yet is able to drive progression of adenomas, initiated by inactivation of Apc, to aggressive and invasive intestinal adenocarcinomas. This result is consistent with our previous findings that Pik3ca H1047R expression alone does not induce tumourigenesis in the ovary [9] or mammary gland [13] .
Mutations in the APC gene are observed in over 80% of CRCs [5] and ~30% of sporadic CRCs possess PIK3CA mutations [7, 8] . Analysis of The Cancer Genome Atlas (TCGA) Network database of 212 CRCs found 14% harboured mutations in both PIK3CA and APC (Supplementary figure 3, [16] ). This cooperative interaction -catenin and PI3K pathways in cancer is supported by previous studies showing loss of Apc together with Pten, a negative regulator of the PI3K enzyme, synergize in the progression of intestinal [17] , ovarian [18] and bladder [19] tumourigenesis. Furthermore, PIK3CA mutations are commonly co-expressed with -catenin mutation in 14% of CRCs [16] . When extended to include other -catenin pathways (PIK3R1 and PTEN, and CTNNB1, respectively), this increases to ~22% of cases which possess a mutation or homozygous deletion in one or more genes in both of these pathways [16] , further highlighting the importance of these two signalling cascades in CRC tumourigenesis.
Cdx2 is required for the regulation of intestinal epithelium homeostasis, development and differentiation [20] . Loss of CDX2 mRNA and CDX2 protein expression has previously been associated with increased invasiveness in human CRC cell lines and poor prognosis in ~80% of poorly differentiated, advance stage adenocarcinoma samples from patients [20, 21] . Thus, loss of Cdx2 expression in Pik3ca
H1047R
:Apc 580D/580D tumours is consistent with them being advanced stage aggressive carcinomas as observed in late stage CRCs in humans.
Cdx2 is also considered to be a tumour suppressor in the adult colon. This is considered to be the result of down-regulation, not genetic alterations, due to the low number of CDX2 mutations observed in CRCs [20] [21] [22] [23] . In vitro studies demonstrated PTEN stimulated expression of Cdx2 in colon cancer cell lines while inhibition of PI3K by wortmannin also produced a similar effect suggesting that Cdx2 is a target of the PTEN/PI3K signalling pathway [24] . As such, we postulate that constitutive activation of the PI3K pathway by the Pik3ca H1047R mutation in our system may be down regulating Cdx2 and its action as a tumour suppressor further contributing to the intestinal tumourigenesis observed.
Our data contrasts with a recent study where the transgenic expression of a constitutively active PI3K protein was sufficient to initiate aggressive tumour formation in the mouse colon within 60 days [25] which became slightly more aggressive upon spontaneous loss of Apc [26] . The tumourigenesis observed with PI3K activation alone in their model may be due to the different mutant protein used to dominantly activate the PI3K enzyme p85 compared to our single amino acid substitution). Also, they used a transgenic approach to express their mutant PI3K which is likely to result in the over-expression of PI3K and potentially within cells that may not normally express PI3K [25] . In our model, both expression of the Pik3ca H1047R mutation and loss of both Apc alleles are targeted to the same cell in the intestine and, importantly, the Pik3ca H0147R mutation is knocked-in to the endogenous gene and thus expression is under the control of the endogenous promoter. As a result, the mutant protein is expressed at physiological levels and only in cells that normally express Pik3ca. Thus our model more accurately reflects the scenario of a heterozygous somatic mutation, as occurs in human CRC.
Evidence is growing that Pik3ca
H1047R mutation is a weak oncogene, and that multiple hits within the PI3K pathway itself, or in other oncogenic pathways, are necessary for it to contribute to tumourigenesis [9, 13] . Our current data further supports these findings, indicating that Pik3ca mutations alone, when expressed at physiological levels, are unable to initiate tumourigenesis in the intestines but have a role in driving the progression of adenomas to invasive adenocarcinomas.
The ability of Pik3ca
H1047R to cooperate with Apc loss to drive progression to adenocarcinoma implies that therapeutic targeting of the PI3K pathway could be beneficial in limiting disease progression in CRC patients. Furthermore, this novel model of intestinal carcinoma will provide a valuable tool for further examining the role of the PI3K signalling cascade in CRC.
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